FCM
IDXX icon

Fourpath Capital Management’s Idexx Laboratories IDXX Stock Holding History

Fourpath Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-310
Closed -$157K – 485
2024
Q3 		$157K Buy
+310
New +$151K 0.03% 236

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fourpath Capital Management's IDXX Position: Q4 2024 in Review

Fourpath Capital Management sold out of Idexx Laboratories (IDXX) in Q4 2024, closing a stake of 310 shares — an estimated $157K sold.

Fourpath Capital Management first reported a position in IDXX in Q3 2024 and held it in 1 quarter. The position peaked at $157K in Q3 2024. 1,123 funds tracked by Wall St. Rank hold IDXX as of Q4 2024.

  • Fourpath Capital Management reported no remaining Idexx Laboratories position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 310 Idexx Laboratories shares in Q4 2024, an estimated $157K.
  • Fourpath Capital Management first reported a position in Idexx Laboratories in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's Idexx Laboratories position peaked at $157K in Q3 2024.
  • 1,123 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.